Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.
Company Details
- Employees
- 15
- Industry
- Biotechnology
- Website
- bioncotech.com
- Keywords
- Barcelona.
Highlight Therapeutics Sl Questions
Highlight Therapeutics Sl's website is bioncotech.com
Highlight Therapeutics Sl's LinkedIn profile is https://es.linkedin.com/company/highlight-therapeutics
Highlight Therapeutics Sl has
15 employees.
View email and phone details for 15
employees at Highlight Therapeutics Sl.
Highlight Therapeutics Sl's industry is
Biotechnology
Highlight Therapeutics Sl's top competitors are
Oryzon Genomics Sa,
Arthex Biotech,
Peptomyc,
Splicebio,
Uza,
Biovegen - Plataforma Tecnológica De Biotecnología Vegetal,
Ona Therapeutics,
Aelix Therapeutics,
Integra Therapeutics,
Minoryx Therapeutics.
Highlight Therapeutics Sl's categories are Biotechnology
